ArriVent BioPharma (AVBP) Q3 2024 earnings summary

Executive summary

• Clinical-stage biopharma focused on cancer therapeutics, with lead candidate firmonertinib in multiple trials for EGFR-mutant NSCLC, including pivotal Phase 3 studies.

• Firmonertinib demonstrated robust anti-tumor activity in front-line EGFR PACC mutant NSCLC, including patients with brain metastases, with a manageable safety profile.

• Achieved Breakthrough Therapy and Orphan Drug Designations for firmonertinib; positive interim data reported in 2024 for key trials.

• Completed IPO in January 2024, raising $183.2 million; all preferred stock converted to common shares.

• Top-line pivotal data from the global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC with EGFR exon 20 insertion mutations expected in 2025.

Financial highlights

• Net loss of $20.6 million for Q3 2024, and $59.9 million for the nine months ended September 30, 2024, up from $48.1 million year-over-year.

• Research and development expenses rose to $20.1 million in Q3 2024 and $58.9 million for the nine months, mainly due to higher headcount and clinical expenses.

• General and administrative expenses increased to $4.1 million in Q3 2024 and $11.8 million for the nine months, reflecting public company infrastructure costs.

• Interest income was $3.7 million in Q3 2024 and $10.7 million for the nine months, reflecting higher cash balances post-IPO.

• Cash and cash equivalents totaled $282.9 million as of September 30, 2024, up from $150.4 million at year-end 2023.

Outlook and guidance

• Cash runway expected to fund operations into 2026, based on current plans and assumptions.

• Anticipates continued increases in R&D and G&A expenses as clinical programs and headcount expand.

• Dose expansion for the SHP2 inhibitor combination study in classical EGFR mutant NSCLC expected in Q4 2024.

• Update on Phase 1b PACC study and plans for a potential registration study anticipated in the first half of 2025.

• Selection of a next-generation ADC candidate for solid tumors expected by late 2024 or early 2025.